Because upregulation of TXNDC5 expression is restricted in activated cardiac fibroblasts, targeting TXNDC5, therefore, could inhibit CF with fewer undesired side effects than targeting TGFβ and RAAS. This evidence concerns the gene TGFB1 and cystic fibrosis.